$16.17 $0.56 (3.6%)

03:22 PM EDT on 05/21/19

Iovance Biotherapeutics Inc (NASDAQ:IOVA)

CAPS Rating: 1 out of 5

Current Price $16.17 Mkt Cap $1.4B
Open $15.72 P/E Ratio 0.00
Prev. Close $15.61 Div. (Yield) $0.00 (0.0%)
Daily Range $15.65 - $16.37 Volume 394,314
52-Wk Range $8.31 - $16.57 Avg. Daily Vol.

Caps

How do you think NASDAQ:IOVA will perform against the market?

Add Stock to CAPS Watchlist

All Players

20 Outperform
26 Underperform
 

All-Star Players

6 Outperform
19 Underperform
 

Wall Street

1 Outperform
1 Underperform
 

Top NASDAQ:IOVA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

zzlangerhans (99.81)
Submitted June 08, 2016

#zzporte has owned Lion since 2014 but I never could get excited enough about the position to enter a green thumb. The stock has gyrated quite a bit since we took our initial position but we never took advantage of the cycles and I recently… More

NASDAQ:IOVA VS S&P 500 (SPY)

NASDAQ:IOVA Summary

Recent Community Commentary

Read the most recent pitches from players about IOVA.

Recs

0
Member Avatar SmartAce (99.97) Submitted: 5/15/2017 12:03:05 PM : Underperform Start Price: $6.13 NASDAQ:IOVA Score: -144.13

Sometimes when I'm sitting in a swivel chair, I'll turn around quickly and smile and pretend I'm in the opening credits of a sitcom.

Recs

2
Member Avatar zzlangerhans (99.81) Submitted: 6/8/2016 9:27:33 AM : Underperform Start Price: $8.20 NASDAQ:IOVA Score: -61.24

#zzporte has owned Lion since 2014 but I never could get excited enough about the position to enter a green thumb. The stock has gyrated quite a bit since we took our initial position but we never took advantage of the cycles and I recently liquidated the last of our position. The impetus to get out of Lion was a very weird day of trading last Friday in which the stock jumped from 6 to the mid 8's after announcement of a large below market dilutive financing at 4.75. I've never seen a stock rise after a below market financing before, and I never would have imagined it could happen by 50%. Usually a below market financing results in the stock closing even lower than the financing price because the discount is perceived as a sign of weakness. In this case the effective market cap rose from 292M (6 x 49M shares) to 593M (8.6 x 69M shares) during the trading day. That's an additional 300M in cap for raising 100M in cash.

I didn't see much commentary pointing out this completely bizarre reaction in share price, athough there were a couple of articles pointing out the simultaneous announcement of a new CEO. I'm sure the new CEO is great, but she wasn't the CEO of anything a month ago and no one hired her to be their CEO then. Just saying. And no one executive is worth 200M of additional cap anyway. Meanwhile, Lion continues the excruciatingly slow progress of their TIL pipeline. I feel like I've been hearing about TILs since I was in high school, and if they were going to be anything they would have been something by now. Lion hasn't even completed enrollment in a midstage trial. Before long this stock is going to find its way back to the 4.75 level that the recent investors got to buy at.

Recs

6
Member Avatar jed71 (99.72) Submitted: 7/7/2014 12:07:47 PM : Underperform Start Price: $6.90 NASDAQ:IOVA Score: -88.73

Not a long pitch here, I've got to get back to work. Just a few copy and paste's from the recent 10-Q. I am a HUGE fan of 1 for 100 reverse stock splits so felt I had to share this information. Company has no revenues to inception (back to 2007) and has changed business plans (restarted an inactive company in 2011) :

"Lion Biotechnologies, Inc. (the “Company,” “we,” “us” or “our”) was originally incorporated under the laws of the state of Nevada on September 17, 2007. Until March 2010, we were an inactive company known as Freight Management Corp. On March 15, 2010, we changed our name to Genesis Biopharma, Inc., and in 2011 we commenced our current business. On September 26, 2013, we amended and restated our Articles of Incorporation to, among other things, change our name to Lion Biotechnologies, Inc., effect a 1-for-100 reverse stock split (pro-rata reduction of outstanding shares) of our common stock, increase (after the reverse stock split) the number of our authorized number of shares of common stock to 150,000,000 shares, and authorize the issuance of 50,000,000 shares of “blank check” preferred stock, $0.001 par value per share."

"We have not had any revenues and are still in the development stage. As shown in the accompanying condensed financial statements, we have incurred a net loss of $2,259,514 for the three months ended March 31, 2014 and used $2,267,363 of cash in our operating activities during the three months ended March 31, 2014. On November 5, 2013, in a private placement (the “Private Placement”), we issued and sold 3,145,300 shares of common stock, 17,000 shares of Series A Convertible Preferred Stock, and warrants to purchase 11,645,300 shares of common stock for an aggregate purchase price of $23,290,600. The net proceeds of the Private Placement were approximately $21,985,000. As a result of the foregoing financing, as of March 31, 2014, we had $17,943,877 of cash or cash equivalents on hand, stockholders’ equity of $16,806,053 and had working capital of $16,958,482."

"Despite the amount of funds that we raised in the Private Placement, the estimated cost of completing the development of our TIL therapy, and of obtaining all required regulatory approvals to market those product candidates, is substantially greater than the amount of funds we currently have available. While we believe that our existing cash balances will be sufficient to fund our currently planned level of operations for at least twelve months, we will have to obtain additional funds through various financing sources, including possible sales of our securities and strategic alliances with other pharmaceutical or biopharmaceutical companies, in order to fund all of our anticipated product development costs."

Leaderboard

Find the members with the highest scoring picks in IOVA.

Score Leader

PoolSkunk

PoolSkunk (72.08) Score: +212.09

The Score Leader is the player with the highest score across all their picks in IOVA.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
DorminABC 99.84 7/25/2011 Underperform NS $154.00 -89.52% +115.00% +204.52 0 Comment
mrmrmrj 55.99 8/31/2017 Outperform 5Y $5.70 +183.16% +16.17% +166.99 0 Comment
Speedster 96.55 9/5/2017 Outperform 5Y $6.20 +160.32% +16.01% +144.31 0 Comment
TruffelPig < 20 3/1/2016 Outperform 5Y $5.54 +191.34% +47.10% +144.24 0 Comment
charityfund 52.86 6/5/2017 Outperform 3M $6.25 +158.24% +17.58% +140.66 0 Comment
Bosscats 38.04 12/9/2016 Outperform 5Y $6.90 +133.91% +27.09% +106.83 0 Comment
manirg < 20 10/16/2015 Outperform 5Y $6.65 +142.71% +41.29% +101.41 0 Comment
portefeuille 98.19 5/23/2014 Outperform 5Y $6.50 +148.31% +50.69% +97.62 0 Comment
wmtworker 78.66 1/4/2018 Outperform 5Y $8.30 +94.46% +5.77% +88.69 0 Comment
ababrmon 88.48 8/3/2015 Outperform 1Y $7.96 +102.83% +36.28% +66.55 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackBRileyandCo < 20 4/10/2018 Outperform NS $15.70 +2.80% +8.54% -5.74 0 Comment
TrackJimCramer 86.03 6/26/2015 Underperform 3W $8.84 +82.58% +36.54% -46.04 0 Comment
TrackJimCramer 86.03 3/18/2015 Outperform 3W $12.99 -31.95% +0.18% -32.12 6/26/2015 @ $8.84 0 Comment

Advertisement